Condition: Schizophrenia · Bipolar Disorder · Autism Spectrum Disorder · Sponsor: Intra-Cellular Therapies, Inc.
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.
This description comes directly from the study's public registry record.
ITI Clinical Trials · 646 440-9333 · ITCIClinicalTrials@itci-inc.com
Always discuss trial participation with your own doctor first.
| Southwest Autism Research and Resource Center | Phoenix, Arizona, United States | Recruiting |
| Pillar Clinical Research, LLC | Little Rock, Arkansas, United States | Recruiting |
| Advanced Research Center, Inc | Anaheim, California, United States | Recruiting |
| National Institute Of Clinical Research | Garden Grove, California, United States | Recruiting |
| Excell Research Inc | Oceanside, California, United States | Recruiting |
| Inland Psychiatric Medical Group Inc | Redlands, California, United States | Recruiting |
| University Of California - Davis | Sacramento, California, United States | Recruiting |
| University Of California San Diego | San Diego, California, United States | Completed |
| Next Level Clinical Trials, LLC | West Covina, California, United States | Recruiting |
| MCB Clinical Research Centers LLC | Colorado Springs, Colorado, United States | Completed |
| Royal Palm Clinical Research | Fort Myers, Florida, United States | Suspended |
| Sarkis Clinical Trials | Gainesville, Florida, United States | Recruiting |
+ 49 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06229210